Showing 7481-7490 of 8649 results for "".
- Ocuphire to Present at Multiple Ophthalmic Conferences in Julyhttps://modernod.com/news/ocuphire-to-present-at-multiple-ophthalmic-conferences-in-july/2479363/Ocuphire Pharma announced that Jay S. Pepose, MD, Medical Advisor and Board Director, will be presenting two papers on presbyopia and reversal of mydriasis (RM) at the 2021 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting on July 23-27, 2021 and that Mina Sooch, CEO and
- FDA, CDC Say No Need for COVID-19 Booster Vaccines in US At This Timehttps://modernod.com/news/fda-cdc-say-no-need-for-covid-19-booster-vaccines-in-us-at-this-time/2479358/The FDA and the US Centers for Disease Control and Prevention (CDC) said that people who have been fully immunized against COVID-19 do not require a booster vaccine at this time, according to a FirstWord report. The jo
- Sight Sciences Pitches $150M IPO for Its Glaucoma, Dry Eye Deviceshttps://modernod.com/news/sight-sciences-pitches-150m-ipo-for-its-glaucoma-dry-eye-devices/2479355/Sight Sciences hopes to see its way to nearly a $1 billion valuation through a $150 million Nasdaq IPO, according to a Fierce Biotech report. By going public, the Menlo Par
- Mikajaki Partners With Segula Technologies to Develop Ophthalmic Diagnosis Devicehttps://modernod.com/news/mikajaki-partners-with-segula-technologies-to-develop-ophthalmic-diagnosis-device/2479353/Swiss startup Mikajaki is teaming up with engineering group Segula Technologies to develop the first operational series of EyeLib, an automated diagnostic station that aims to revolutionize the management of the growing number of patients with vision disorders, according to a company news release
- Bausch + Lomb Completes Enrollment of Second Phase 3 Study for NOV03https://modernod.com/news/bausch-lomb-completes-enrollment-of-second-phase-3-study-for-nov03/2479349/Bausch + Lomb and Novaliq announced the second of two phase 3 (MOJAVE) studies evaluating the investigational drug NOV03 (perfluorohexyloctane) as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with meibomian gland dy
- Phoenix, Knoxville, Kansas City Stand Out for Retinal Treatment Opportunity in the UShttps://modernod.com/news/phoenix-knoxville-kansas-city-stand-out-for-retinal-treatment-opportunity-in-the-us/2479346/The Phoenix metro area has the highest number of vitrectomies per provider in the US, while Knoxville, Tennessee, stands out for above average annual intravitreal injection volumes per provider. Kansas City is set apart by its high concentrations of high-volume IVT providers, according to Market
- Oasis TEARS PF PLUS Preservative-Free Lubricant Eye Drops Now Delivered in a Bottlehttps://modernod.com/news/oasis-tears-pf-plus-preservative-free-lubricant-eye-drops-now-delivered-in-a-bottle/2479338/Oasis Medical is launching Oasis TEARS PF PLUS preservative-free lubricant eye drops delivered in a 10mL bottle for multiuse. Lubricant eye drops, which are packaged in traditional multi-use bottles, contain preservatives to prevent microbial growth. Preservative-free lubricant eye drops a
- GenSight Biologics Reports Topline Results From REFLECT Phase 3 Trial, Confirming Lumevoq Efficacyhttps://modernod.com/news/gensight-biologics-reports-topline-results-from-reflect-phase-3-trial-confirming-lumevoq-efficacy/2479336/GenSight Biologics reported key efficacy and safety findings at 1.5 years (78 weeks) post-treatment in the REFLECT phase 3 clinical trial for Lumevoq. The results show better visual acuity improvements from bilateral intravitreal injections of the gene therapy compared to a unilateral injection.<
- Ocuphire’s VEGA-1 Phase 2 Trial in Presbyopia Meets Primary and Secondary Endpointshttps://modernod.com/news/ocuphires-vega-1-phase-2-trial-in-presbyopia-meets-primary-and-secondary-endpoints/2479332/Ocuphire Pharma announced that the VEGA-1 phase 2 clinical trial evaluating the efficacy and safety of Nyxol in combination with low-dose pilocarpine (LDP) in presbyopic subjects successfully met its primary and many secondary endpoints. On the strength of these results, Ocuphire plans to move in
- Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, Byoovizhttps://modernod.com/news/samsung-bioepis-and-biogen-receive-positive-chmp-opinion-for-ranibizumab-biosimilar-byooviz/2479327/Samsung Bioepis Biogen announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Byooviz, a biosimilar candidate referencing Lucentis (ranibizumab), also known as SB11. Ranibizumab is an anti-VEGF (vasc